ABSTRACT
INTRODUCTION
Acute pain is prevalent and often under-treated [1, 2] that results in increased suffering and distress, delayed rehabilitation and healing, and may transition to chronic pain (a process known as chronification) [3, 4] . Acute pain may occur following surgical procedures, trauma, or illness. Even when acute pain is predictable and occurs in a controlled setting (such as inpatient surgery), pain is often lessthan-optimally treated. In a survey of 250 adults who had surgery as an in-or outpatient in the last 5 years, 82% reported at least some degree of pain in the period of up to 2 weeks after surgery; 21% and 18% of these respondents categorized the postsurgical pain as severe or extreme, respectively [5] . In a French survey among 750 adult patients 24 h following surgery, 87% reported postsurgical pain with half (50.9%) categorizing that pain as severe [6] .
A German multicenter study (n = 2252 patients who underwent surgery or other procedure) found that 88% of patients were in pain 24 h after their treatment, with non-surgical patients experiencing slightly higher rates of undertreated pain [7] . In a survey of 50,869 patients with acute pain of various etiologies (surgery, trauma, postherpetic neuralgia, low back pain, and other conditions), 44% reported inadequate analgesia [8] .
The pharmacological armamentarium for managing acute pain includes nonopioid agents, notably acetaminophen (paracetamol), nonsteroidal anti-inflammatory drugs (NSAIDs), and anticonvulsants [9] , although their efficacy in acute pain is debatable; and opioids for moderate to severe or very severe pain. Risks and benefits attach to each of these agents. Acetaminophen has been associated with liver damage [10] . NSAIDs have been associated with gastrointestinal side effects and cardiovascular adverse events [11, 12] . Opioids are associated with potentially treatment-limiting side effects. In a survey of 50,869 patients with acute pain, 37% of those treated with a strong opioid discontinued their medication before pain resolved because of intolerable side effects [8] .
Thus, the undertreatment of acute pain may sometimes be due to the fact an analgesic product was not tolerated, rather than the fact that no analgesics were prescribed. In an open-label extension study of the above trial lasting at least 14 days, tolerability of XARTEMIS TM XR was consistent with that of an opioid product and AEs occurred in 43.8% of patients [42] . The most common AEs reported in this extension study were nausea (17.8%), vomiting (7.5%), and constipation (6.2%).
LONG-ACTING FORMULATIONS
In an analysis of 20 studies of XARTEMIS TM XR (n = 2641 patients total), the number needed to treat for at least 50% pain relief was 4.6 (95% confidence interval, range 2.9-11) for singleentity oxycodone and 2.7 (95% confidence interval, range 2.4-3.1) for oxycodone/ acetaminophen 10/650 mg (an IR product) [35] .
CONSIDERATIONS FOR THE USE OF ACETAMINOPHEN IN FIXED-DOSE PRODUCTS
Acetaminophen is the most frequently consumed analgesic in the US [43, 44] . The FDA has launched various public health initiatives regarding this familiar drug's potential hepatotoxicity, and it recommends that adult doses be limited to no more than 4000 mg per day, which is higher than the 3000 mg maximum daily dose on current products marketed by McNeill Consumer
Healthcare, a Johnson & Johnson company [45, 46] . Since this total daily dose is cumulative from all sources, the FDA further limits the dose of acetaminophen allowed in prescription combination products [47] . Despite these efforts, however, consumers may be unaware of potential acetaminophen toxicity or be unaware of all of the sources of acetaminophen in their medicine cabinets [48] [49] [50] . Long-acting oxycodone/acetaminophen seems to be an important new option. It might offer equianalgesic benefits to patients with acute pain without exposing them to the greater quantity of opioids contained in singleentity opioid therapy. It will offer more stable serum concentrations, and its convenient dosing might improve patient adherence.
CONCLUSION
To the armamentarium for pain control has been added a long-acting fixed-dose combination product of oxycodone/acetaminophen (7. 
